尿激酶型纤溶酶原激活物及其特异受体和抑制物与肝细胞癌浸润转移 …

目的 研究尿激酶型纤酶原激活物及其特异受体和抑制物（ＰＡ－Ｉ）与肝细胞癌（ＨＣＣ）的关系及其在ＨＣＣ浸润转移中的作用。方法 用ｕＰＡ、ＰＡＩ－１单克隆抗体和ｕＰＡ－Ｒ多缺检测ｕＰＡ、ＰＡＩ－１和ＵＰＡ－Ｒ在４８例ＨＣＣ和１２对照组中蛋白水平的表达。结果癌与癌及对照组比较,ＵＰＡ、ＵＰＡ－Ｒ和ＰＡＩ－１膜上免疫染色阳性率明显升高,Ｐ〈０．０５。在侵袭性病例中,ＵＰＡ和ＵＰＡ－Ｒ阳性为１６／２２和１９

Urokinase-type plasminogen activator (uPA), uPA receptor (uPA-R) and inhibitors (PA I -1) expression in hepatocellular carcinoma in relation to cancer invasion/metastasis and prognosis

OBJECTIVE: To study the relevance of uPA, uPA-R and PA I -1 to hepatocellular cancer (HCC). METHODS: The expression at protein level for uPA, uPA-R and PA I -1 was examined in 48 cases of HCC and 12 cases of benign tumors of the liver (as control) immunohistochemically. RESULTS: When compared to HCC-adjacent normal liver tissue and the control, positive rates of immune staining for uPA, uPA-R and PA I -1 on cell membrane were significantly higher in HCC cells (P < 0.05). Positive staining of uPA and uPA-R was seen in 16 of 22 and 19 of 22 cases of HCC with invasion, respectively (P < 0.01 and < 0.001). In 8 of 8 cases with cancer emboli, and in 6 of 6 cases with lymph node metastasis was the expression of uPA-R positive. Compared with 2 of 17 cases without recurrence, uPA-R was positive in 15 of 17 recurrent cases (P < 0.01). In 36 cases who survived, 17 was positive for uPA-R and 15 for PA I -1, while in 12 cases who died 2 years after surgery, 12 and 9 cases were positive for uPA-R and PA I -1, respectively (P < 0.01 and < 0.05). In 15 cases positive for all three parameters, 11 had cancer invasion and 7 died in 2 years, while in the controls with negative staining 2 had invasion and none died in 2 years (P < 0.05). CONCLUSION: Expression of uPA, uPA-R and PA I -1 is increased in HCC, and uPA and uPA-R may contribute significantly to HCC invasion and metastasis. uPA-R and PA I -1 are associated with poor prognosis.